Background No new agent has improved overall survival in patients with unresectable or
metastatic urothelial carcinoma when added to first-line cisplatin-based chemotherapy …

T cell infiltration in the tumour microenvironment (TME) is a prerequisite for sustained
antitumour immune responses. However, identifying predictive biomarkers that quantify T …

Methods A non-systematic, literature search was conducted between March 5, 2023 and
November 30, 2023 on PubMed using “perioperative period”,“MIBC”,“chemotherapy”,“ …

Immuno-oncology (IO) has made monumental gains in the past decade in the genitourinary
space. In this review, we highlight advances with IO in renal cell carcinoma where it now has …

Simple Summary A group of experts was invited to speak at the first Immune Assessment
symposium held in Chicago, IL in early October of 2023. The combined knowledge …

Gene editing technologies help identify the genetic perturbations driving tumour initiation,
growth, metastasis and resistance to therapeutics. This wealth of information highlights …

Bladder cancer (BC) is a prevalent malignancy with significant morbidity and mortality. Over
the years, the landscape of bladder cancer treatment has witnessed notable advancements …

Background The tumour stroma is associated with unfavourable prognosis in diverse solid
tumours, but its prognostic and predictive value in bladder cancer (BCa) is unclear. Methods …

Simple Summary Metastatic bladder carcinoma is a cancer with a poor prognosis, for which
treatments have remained the same for several decades. Immunotherapy has revolutionized …

The standard treatment paradigm for muscle invasive bladder cancer has been neoadjuvant
cisplatin-based chemotherapy followed by radical cystectomy. However, efforts are ongoing …